A quantitative, Bayesian-informed approach to gene-specific variant classification: Updated Expert Panel recommendations improve classification of TP53 germline variants for Li-Fraumeni syndrome

Fortuno, C; Frone, MN; Mester, J; de la Hoya, M; Mai, PL; Pesaran, T; Achatz, MI; Bassett, R; Bustamante, C; Crowley, S; de Andrade, KC; Evans, DG; Feng, B; Fuqua, L; Harrell, MI; Hatton, JN; Huether, R; Kesserwan, C; Lee, K; MacFarland, SP; Maciaszek, JL; Maxwell, K; McGoldrick, K; Murphy, M; Nehoray, B; Penkert, J; Pinto, EM; Plon, SE; Schwartz-Levine, A; Thompson, AS; Wang, W; Zambetti, GP; Zelley, K; James, PA; Savage, SA; Kratz, CP; Spurdle, AB

Author(s): Fortuno, C; Frone, MN; Mester, J; de la Hoya, M; Mai, PL; Pesaran, T; Achatz, MI; Bassett, R; Bustamante, C; Crowley, S; de Andrade, KC; Evans, DG; Feng, B; Fuqua, L; Harrell, MI; Hatton, JN; Huether, R; Kesserwan, C; Lee, K; MacFarland, SP; Maciaszek, JL; Maxwell, K; McGoldrick, K; Murphy, M; Nehoray, B; Penkert, J; Pinto, EM; Plon, SE; Schwartz-Levine, A; Thompson, AS; Wang, W; Zambetti, GP; Zelley, K; James, PA; Savage, SA; Kratz, CP; Spurdle, AB;
Details: Publication Year 2025-10-22,Volume 17,Issue #1,Page 128
Journal Title: Genome Medicine
Publication Type: Guideline
Abstract: BACKGROUND: Germline pathogenic variants in TP53 cause Li-Fraumeni syndrome, with significantly elevated cancer risk from infancy. Accurate classification of TP53 variants is essential to guide clinical management and surveillance, yet many variants remain classified as variants of uncertain significance (VUS). To improve classification accuracy and reduce the proportion of VUS, the ClinGen TP53 Variant Curation Expert Panel (VCEP) has updated its specifications. METHODS: The updated specifications incorporate the latest ClinGen recommendations and methodological advances, providing greater granularity for multiple evidence types, and also introduce the novel use of variant allele fraction as evidence of pathogenicity, particularly in the context of clonal hematopoiesis. Whenever feasible, the VCEP followed a data-driven approach using likelihood ratio-based quantitative analyses to guide code application and determine strength modifications, while also factoring in expert judgment. Proposed modifications were first discussed in working group meetings and then subjected to comprehensive review during monthly general VCEP meetings to reach consensus. RESULTS: The performance of new specifications was compared to that of the old specifications for 43 pilot variants, and led to both decreased VUS and increased certainty, with clinically meaningful classifications for 93% of variants. CONCLUSIONS: The updated TP53 specfications are expected to reduce VUS rates, increase inter-laboratory concordance, and improve medical management for individuals with germline TP53 variants. The most current version is available at the ClinGen Criteria Specifications Registry (CSpec): https://cspec.genome.network/cspec/ui/svi/svi/GN009 .
Publisher: BioMed Central
Keywords: *Li-Fraumeni Syndrome/genetics/diagnosis; Humans; *Germ-Line Mutation; *Tumor Suppressor Protein p53/genetics; Bayes Theorem; Genetic Predisposition to Disease; Tp53; ACMG guidelines; ClinGen Variant Curation Expert Panel (VCEP); Li-Fraumeni syndrome
Department(s): Familial Cancer Centre
Publisher's Version: https://doi.org/10.1186/s13073-025-01536-3
Open Access at Publisher's Site: https://doi.org/10.1186/s13073-025-01536-3
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2025-11-11 04:09:27

Last Modified: 2025-11-11 04:09:46